Abliva AB

Abliva AB was a Lund-based Swedish biotech developing treatments for primary mitochondrial disease (PMD), a group of rare, debilitating disorders.

Its lead candidate, KL1333, is being evaluated in a global Phase 2, potentially registrational clinical trial, in adults with PMD.

Hadean Ventures backed Abliva since 2020, and supported the company strategically through the board of directors – driving the company through regulatory milestones, positive clinical readouts and evolving the management team. The current program delivered encouraging interim data in 2024, reinforcing Abliva’s path toward meaningful therapies for patients.

In December 2024, Pharming announced a recommended cash offer for Abliva with a record-breaking cash premium at +227% - well above the ~75% median premium seen in 2024 life-sciences M&A.

The transaction completed in February 2025, marking a successful exit for Hadean and a strong outcome for European life-science venture.

This case showcases how specialist European VCs can accelerate Nordic science to global impact – combining hands-on company scaling, syndicate leadership, and long-term committed capital.

For patients with PMD and for Europe’s biotech ecosystem, Abliva acts as a blueprint for partnership, impact, and the value venture capital can add in the context of a public company.